222 related articles for article (PubMed ID: 23585192)
81. The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.
Perez EA; Baehner FL; Butler SM; Thompson EA; Dueck AC; Jamshidian F; Cherbavaz D; Yoshizawa C; Shak S; Kaufman PA; Davidson NE; Gralow J; Asmann YW; Ballman KV
Breast Cancer Res; 2015 Oct; 17(1):133. PubMed ID: 26429296
[TBL] [Abstract][Full Text] [Related]
82. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
83. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
84. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Loi S; Sirtaine N; Piette F; Salgado R; Viale G; Van Eenoo F; Rouas G; Francis P; Crown JP; Hitre E; de Azambuja E; Quinaux E; Di Leo A; Michiels S; Piccart MJ; Sotiriou C
J Clin Oncol; 2013 Mar; 31(7):860-7. PubMed ID: 23341518
[TBL] [Abstract][Full Text] [Related]
85. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
Baselga J; Cortés J; Im SA; Clark E; Ross G; Kiermaier A; Swain SM
J Clin Oncol; 2014 Nov; 32(33):3753-61. PubMed ID: 25332247
[TBL] [Abstract][Full Text] [Related]
86. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
[TBL] [Abstract][Full Text] [Related]
87. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
[TBL] [Abstract][Full Text] [Related]
88. Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.
Pivot X; Fumoleau P; Pierga JY; Delaloge S; Bonnefoi H; Bachelot T; Jouannaud C; Bourgeois H; Rios M; Soulié P; Jacquin JP; Lavau-Denes S; Kerbrat P; Cox D; Faure-Mercier C; Pauporte I; Gligorov J; Curtit E; Henriques J; Paget-Bailly S; Romieu G
Eur J Cancer; 2017 Aug; 81():151-160. PubMed ID: 28624696
[TBL] [Abstract][Full Text] [Related]
89. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.
Green AR; Barros FF; Abdel-Fatah TM; Moseley P; Nolan CC; Durham AC; Rakha EA; Chan S; Ellis IO
Breast Cancer Res Treat; 2014 May; 145(1):33-44. PubMed ID: 24706169
[TBL] [Abstract][Full Text] [Related]
90. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
Dowsett M; Procter M; McCaskill-Stevens W; de Azambuja E; Dafni U; Rueschoff J; Jordan B; Dolci S; Abramovitz M; Stoss O; Viale G; Gelber RD; Piccart-Gebhart M; Leyland-Jones B
J Clin Oncol; 2009 Jun; 27(18):2962-9. PubMed ID: 19364966
[TBL] [Abstract][Full Text] [Related]
91. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.
Cheng H; Ballman K; Vassilakopoulou M; Dueck AC; Reinholz MM; Tenner K; Gralow J; Hudis C; Davidson NE; Fountzilas G; McCullough AE; Chen B; Psyrri A; Rimm DL; Perez EA
Br J Cancer; 2014 Sep; 111(6):1065-71. PubMed ID: 25117817
[TBL] [Abstract][Full Text] [Related]
92. Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ?
Wong FY; Yip CS; Chua ET
World J Surg; 2012 Feb; 36(2):287-94. PubMed ID: 22105650
[TBL] [Abstract][Full Text] [Related]
93. Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study.
Campiglio M; Bufalino R; Sasso M; Ferri E; Casalini P; Adamo V; Fabi A; Aiello R; Riccardi F; Valle E; Scotti V; Tabaro G; Giuffrida D; Tarenzi E; Bologna A; Mustacchi G; Bianchi F; Balsari A; Ménard S; Tagliabue E
Breast Cancer Res Treat; 2013 Aug; 141(1):101-10. PubMed ID: 23942848
[TBL] [Abstract][Full Text] [Related]
94. HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.
Zabaglo L; Stoss O; Rüschoff J; Zielinski D; Salter J; Arfi M; Bradbury I; Dafni U; Piccart-Gebhart M; Procter M; Dowsett M;
Ann Oncol; 2013 Nov; 24(11):2761-6. PubMed ID: 23894039
[TBL] [Abstract][Full Text] [Related]
95. Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years.
Kawai M; Malone KE; Tang MT; Li CI
Cancer; 2014 May; 120(10):1548-56. PubMed ID: 24500704
[TBL] [Abstract][Full Text] [Related]
96. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Harris LN; Ismaila N; McShane LM; Andre F; Collyar DE; Gonzalez-Angulo AM; Hammond EH; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Bast RC; Hayes DF;
J Clin Oncol; 2016 Apr; 34(10):1134-50. PubMed ID: 26858339
[TBL] [Abstract][Full Text] [Related]
97. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.
Widschwendter P; Friedl TW; Schwentner L; DeGregorio N; Jaeger B; Schramm A; Bekes I; Deniz M; Lato K; Weissenbacher T; Kost B; Andergassen U; Jueckstock J; Neugebauer J; Trapp E; Fasching PA; Beckmann MW; Schneeweiss A; Schrader I; Rack B; Janni W; Scholz C
Breast Cancer Res; 2015 Sep; 17(1):129. PubMed ID: 26385214
[TBL] [Abstract][Full Text] [Related]
98. HER-3 status by immunohistochemistry in HER-2-positive metastatic breast cancer patients treated with trastuzumab: correlation with clinical outcome.
Gori S; Foglietta J; Mameli MG; Stocchi L; Fenocchio D; Anastasi P; Iacono D; Del Sordo R; Basurto C; De Angelis V; Sidoni A
Tumori; 2012; 98(1):39-44. PubMed ID: 22495700
[TBL] [Abstract][Full Text] [Related]
99. Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer.
Neugut AI; Hillyer GC; Kushi LH; Lamerato L; Leoce N; Ambrosone CB; Bovbjerg DH; Mandelblatt JS; Hershman DL
Breast Cancer; 2014 Nov; 21(6):780-5. PubMed ID: 24902664
[TBL] [Abstract][Full Text] [Related]
100. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes.
Parinyanitikul N; Lei X; Chavez-MacGregor M; Liu S; Mittendorf EA; Litton JK; Woodward W; Zhang AH; Hortobagyi GN; Valero V; Meric-Bernstam F; Gonzalez-Angulo AM
Clin Breast Cancer; 2015 Apr; 15(2):153-60. PubMed ID: 25454687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
